ReleaseWire Connect

ReportsnReports.com offers a 25% discount on Oil and Gas Supply Demand Outlook in Asia Pacific to 2020 - Growing Appetite for Oil and Gas Changing the Global Consumption Outlook Buy before June,25,2011 and avail a discount of 25% on Oil and Gas Supply Demand Outlook in Asia Pacific to 2020 - Growing Appetite for Oil and Gas Changing the Global Consumption Outlook by GBI Research at ReportsnReports.com.

The report covers the latest information on the revenue and volume of the DRAM Market The report provides a product - based forecast of DRAM up to 2020.

ReportsnReports.com offers a 10% discount on Ethylene Dichloride (EDC) Global Market Dynamics to 2020 – Poly Vinyl Chloride (PVC) Market Continues to Drive the Global Demand Buy before June 25, 2011 and avail a discount of 10% on Ethylene Dichloride (EDC) Global Market Dynamics to 2020 – Poly Vinyl Chloride (PVC) Market Continues to Drive the Global Demand by GBI Research at ReportsnReports.com.

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading power industry executives.

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading mining industry executives. It analyzes how mining industry suppliers’ media spend, marketing and sales strategies and business practices are set to change in 2011–2012. This report gives you access to the media channel spending outlooks, media budgets, marketing agency selection criteria, business challenges and sales tactics of leading suppliers. The report also identifies future growth of buyers and suppliers, M&A and investment expectations. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and sizes.

The Australian opioid market grew from $63m in 2005 to $137m in 2009. Its growth will slow considerably and the market will be worth $182m in 2019. As many new drugs to come on the market will be reformulations, Datamonitor assumes that these will be priced at a similar level as currently available brands in order to receive reimbursement. This means that the value of the market will stabilize.

The opioids market is set to grow from $9.6 billion in 2008 to $11.9 billion in 2018 across the seven major markets. However, the number and diversity of products in late-stage development will limit the commercial potential of individual brands simply due to saturation and price competition in each opioids market.

GBI Research’s research, “Risk Evaluation and Mitigation Strategy (REMS) – Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS”, provides key data, information and analysis on the risk management and mitigation strategies, mandated by the FDA and being implemented by pharmaceutical companies.

The Australian opioid market grew from $63m in 2005 to $137m in 2009. Its growth will slow considerably and the market will be worth $182m in 2019. As many new drugs to come on the market will be reformulations, Datamonitor assumes that these will be priced at a similar level as currently available brands in order to receive reimbursement. This means that the value of the market will stabilize.

GBI Research, the leading business intelligence provider, has released its latest research, “Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market”, which provides insights into global opioids market and market forecast until 2017. The report provides an in-depth analysis of the top seven therapeutic indications for which often opioids are prescribed which includes fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain. The report also examines the global opioids treatment usage patterns for the covered indication. In addition, the report also includes insights into the opioids R&D pipeline.